When ocrelizumab became the first FDA-approved treatment for early forms of multiple sclerosis (MS) in 2017, it offered ...

Three of five patients with advanced colorectal cancer responded to leronlimab, including one complete response lasting five years, according to new data.

Scientists have studied a new target for antibiotics in the greatest detail yet—in the fight against antibiotic resistance.